

Vaginal Microbiota and its Oncological Risk

Victor Manuel Vargas Hernandez

Department of Gynecology, Hospital Juarez of Mexico, Insurgentes Sur 605-1403, Napoles, Mexico.

vvargashernandez@yahoo.com.mx

***Corresponding Author:** Victor Manuel Vargas Hernandez, Department of Gynecology, Hospital Juarez of Mexico, Insurgentes Sur 605-1403, Napoles, CDMX 03810 Mexico.

Abstract

Background: Microbes inhabit all the sites of the human body and play an important role in health; The normal vaginal microbiota is composed mainly of *Lactobacillus*, and these have a role in the carcinogenesis of cervical cancer (both protective and harmful), for the acquisition or persistence of infection by human papillomavirus and subsequent development of cervical precursors and cancer cervical; women with HPV infection have greater microbial diversity and a lower proportion of *Lactobacillus spp*; the use of next-generation sequencing techniques; has identified 5 bacterial groups associated with the severity of the cervical precursor lesions and their modulation towards a stable dominant microenvironment of *Lactobacillus spp.*, promotes the purification of HPV.

Conclusion: The relationship between HPV infection, cervical precursor lesions and vaginal microbiota play a role in the tumor microenvironment; influencing the immune response, susceptibility to infection and development of cervical cancer; together with the other risk factors in the host. Women with vaginal microbiota Vaginal Microbiota of high diversity and cervical pathology should have greater vigilance and / or treatment.

Keywords: Bacterial vaginosis, HPV, HIV, lactobacillus, probiotics, cervical intraepithelial neoplasia, cervical cancer, lactic acid, hormonal contraception, carcinogenesis, community-state types (CSTs), high-grade squamous intraepithelial lesion.

BACKGROUND

Microorganisms inhabit all the sites of the human body and play an important role in health ¹⁻². The vaginal microbiota of healthy women consists of a variety of anaerobic and aerobic microorganisms in equilibrium (or eubiosis) where lactobacilli are predominant, when this balance (or dysbiosis) is lost other microorganisms grow affecting the defense mechanisms (or pathogenesis), which depends on different factors (hormonal, douching, sexual practices, bacterial interactions, host defenses, etc.), promoting inflammatory disorders, loss of barrier function, diseases and even cancer ¹⁻⁴. Lactobacilli produce antimicrobial compounds (hydrogen peroxide, lactic acid, bacteriocin-like substances) that have the ability to adhere and compete for adhesion sites in the vagina with other pathogens, to maintain the homeostasis of vaginal microbiota in the host; the prolonged time of dysbiosis and other risk factors ⁴; They are associated with several types of cancer mainly in the

mucous membranes of the tissues where the bacteria inhabit ⁴. Persistent infection with high-grade human papillomavirus (HPV), mainly (HPV-16/18) are cause necessary for the development of cervical cancer ^{3,4}; in addition, other factors in the local microenvironment, which alter the microbiota vaginal with elevation of pH ⁵⁻⁹.

Lactobacilli prevent genitourinary infections by maintaining a vaginal pH between 3.8 to 4.5, by the production of lactic acid, secretion of antimicrobial compounds and elimination of microorganisms. The composition of MV in women of reproductive age is dominated by lactobacilli, the four predominant species (*Lactobacillus crispatus*, *Lactobacillus gasseri*, *Lactobacillus iners*, *Lactobacillus jensenii*), associated with vaginal health, ^{1,2} in some women, the MV lacks high proportion of lactobacilli and is dominated by a diverse mix of anaerobic and microaerophilic bacteria (*Gardnerella*, *Atopobium*, *Prevotella*, *Sneathia*) associated with bacterial vaginosis^{1,2}, which is

Vaginal Microbiota and its Oncological Risk

characterized by a loss or decrease of *Lactobacillus*, high pH and infiltration of immune cells, anaerobic bacteria growth and complications and obstetric and gynecological infections with higher risk and predisposition to HPV infection, mainly when infection with the human immunodeficiency virus (HIV) coexists; producing changes in the composition of the vaginal microbiota^{3,10-12}.

INFECTION WITH HPV AND VAGINAL MICROBIOTE

HPV infection is common in sexually active women; the majority is transitory; However, other associated factors play important roles in susceptibility, such as local immunity, hormonal and genetic levels. The vaginal microbiota plays a protective role in the health of women, the immune response serves as an indicator of vaginal health^{3,4}; abnormal vaginal microbiota, as in bacterial vaginosis, is associated with increased health risk in the genital tract with spontaneous or recurrent miscarriage, preterm birth, and sexually transmitted infections (STIs), including HIV and HPV; Healthy vaginal microbiota contribute to health in women³. The *Lactobacilli*, are commensals of the vagina that protect from pathogens and infections, through the production of specific metabolites such as bacteriocins that eliminate related bacterial species, with adhesion to the mucosa, biofilm formation, and biosurfactants, which prevent their binding to the epithelium¹⁻⁵. Next generation sequencing (NGS) facilitates the characterization of healthy vaginal microbiota, in 5 main types of group phases or community-state types (CSTs); CST I, II, III and V are dominated by *Lactobacillus crispatus*, *L. gasseri*, *L. iners* and *L. jensenii* respectively, while CST IV has a characteristically low number of *Lactobacillus* spp., and a greater diversity of anaerobic bacteria¹⁻⁴. The vaginal microbiota is dynamic and hormonally influenced with a propensity to become less stable during menstruation and vice versa more stable and less diverse during normal pregnancy⁶. The stability and composition of the vaginal microbiota play an important role in determining the response Innate host immune and susceptibility to infection. Bacterial Vaginosis, (CST IV) is a disorder characterized by a greater diversity of species, with high prevalence, 12 to 50%, in women of reproductive age characterized by depletion of *Lactobacillus* spp., Anaerobic overgrowth and pH High vaginal discharge associated with increased susceptibility to ascending vaginal infection through sensitization and alteration of the host's innate immune system. The Vaginal Microbiota

is influenced by estrogen levels, which also control the thickness of the vaginal epithelial tissue^{3,6}. The vaginal microbiota of the predominantly columnar epithelium as in the immature cervix differs from the squamous and the vaginal microbiota of these immature epithelia contribute to vulnerability to HPV infections. One of the mechanisms associated with the clearance or persistence of HPV infection is Bacterial Vaginosis, which is associated with late HPV clearance and cervical intraepithelial neoplasia (CIN), suggesting that *Lactobacillus* Vaginal Microbiota depletion plays a role^{3,6,10}. In sexually active women it was found that the depletion of *Lactobacillus* spp., *Atopobium* spp. (CST IV) is associated with the slowest regression of HPV, while a microbiota dominated by *Lactobacillus gasseri* (CST II) is associated with the fastest regression rates for HPV^{3-5,10,11}. *Lactobacillus* spp., Confer resistance to HPV infection as well as protect against the colonization of pathogens. The E5 protein of HPV-16 is susceptible to a low pH^{3,4}. Vaginal Microbiota with positive HPV is more diverse than in negative HPV^{3,6,10,11}

Adhesion to the epithelial cells is crucial in the colonization, the invasion allows the bacteria to evade the immune surveillance of the host and to spread to deeper tissues, provoking pro-inflammatory responses that promote bacterial adhesion, to lodge in epithelial cells. HPV infection alters mucosal metabolism and host immunity, causing changes in the structure of the vaginal microbiota^{1-4,10,11}.

CARCINOGENESIS

There are more than 200 HPV genotypes; mainly HPV-16 and 18 that cause 70% CaCu; HPV infection is eliminated by more than 90% within 6-18 months^{3,10}, and only persistently in 10% of infected women. The factors responsible for persistence, which promote the initiation of carcinogenesis, are unknown; Risk factors such as immunodeficiency, age, smoking, oral contraceptives and *Chlamydia trachomatis* infection, which also negatively influence the vaginal microbiota, promote HPV carcinogenesis^{12,13}; Vaginal health is associated with low microbial diversity with a prevalence of *lactobacilli*^{14,15}, preventing the proliferation of exogenous pathogens^{16,17}. Abnormal vaginal microbiota with decreased *Lactobacillus* and increased microbial diversity facilitates the persistence of HPV infection and cancer development; 7.4% of women, of the CST IV subgroup, associated with bacterial vaginosis, together with the genus *Atopobium* spp (CST IV-VB) and sialidase of *G. vaginalis* are risk

Vaginal Microbiota and its Oncological Risk

factors or microbial markers for the persistence of HPV. The changes in the vaginal microbiota influence in 15 to 20% in the development of carcinogenesis without distinguishing if they are causes or effects of the cancer; by diverse mechanisms, like inflammation, immunomodulation, damage to the DNA and production of metabolites in the tumor suppression; Drug manipulation as adjuvants of the vaginal microbiota improves the response to oncological management^{9,18}.

The risk in life to acquire any HPV infection probably exceeds 5% by 80%. HPV genotypes associated with alpha species predominate in the anogenital area, but beta and gamma types of HPV are also detected. Because the lifetime risk of developing cervical cancer is less than 0.6%, cervical cancer is considered a rare complication of a common infection and should be considered HPV as a commensal organism that plays a protective role against HPV^{2,5,7}. The time from infection to the development of cervical cancer is 15 years; although there may be a rapid progression in rare cases^{2,5}.

Not all lactobacilli are necessarily stable or healthy. *L. iners* is present in all women including those with dysbiosis, while *Lactobacillus crispatus* is observed mainly in healthy women, the predominance of *L. iners* predicted the development of bacterial vaginosis, in comparison, to the predominance of *L. crispatus* that is protective against the development of bacterial vaginosis^{2,5,11}. Most women have a relatively stable vaginal microbiota; in those with vaginal microbiota of greater diversity greater instability is observed^{19,20}. Cervical carcinogenesis usually has a long precancerous phase and it is to be determined, what factors determine that the infection persists, progresses or, on the contrary, returns spontaneously^{2,3,8,12}.

In general, HPV is a non-lymphatic infection and the inflammatory response is less than other infections, such as *C. trachomatis*. The initial immune response to acute HPV infections is mediated by the local innate immune system, involving mechanisms such as activation of toll-like receptors and natural killer cells (NK)^{2,5}. Persistent HPV infections are cleared by the adaptive immune response, which depends on the antigen-presenting cells. It is thought that HPV-16 decreases the innate and adaptive immune response; but, local microbial communities also play roles in the regulation of the immune response. The final pathways to cancer result in interference with telomerase activity and viral integration of the HPV E6

and E7 oncoproteins, controlling carcinogenic events (proliferation, senescence and apoptosis). Vaginal microbiota also manipulates these oncoproteins of HPV, by HPV-induced dysbiosis involved in the natural history of the disease^{5,11,16-19}, chronic exposure to inflammation is toxic to cells resulting in DNA damage and carcinogenic changes²⁰⁻²⁵

The communities of vaginal bacteria in healthy women are usually populated by *Lactobacillus* spp., which ensures a low pH, which provides the first line of defense against pathogens^{5,14,19,20}. Bacterial Vaginosis-CST IV is a disorder characterized by a greater diversity of species, with a prevalence of 12 to 50%, which has implications for public health^{19,20}. The intestine is a reservoir for many vaginal microbiota species (healthy or pathogenic), the vagina is protected from the colonization of most intestinal and rectal species that is predictive of the development of vaginosis bacterial in women^{19,20}; epithelial thinning in postmenopausal women is responsible for the change in MV distribution that improves with menopausal hormone therapy^{7,14}. Evaluation of the vaginal flora with the degree of disease (normal, LSIL, HSIL and Cervical Cancer¹⁹⁻²⁵ *L. crispatus* can have a beneficial effect on the HPV burden both in HIV-infected women and in women not infected with HIV (independent of pH)¹².

The highest rates of CST IV (with depletion and high diversity of *Lactobacillus*) were associated with increased severity in women with LSIL, HSIL and cervical cancer, compared with normal women³. The presence of high diversity with *Lactobacillus* depletion in the MV it is related to CaCu instead of the presence of the HPV genotype itself^{3,9,10} and the difference in the composition of the MV is related to an increase in the severity of the precursor lesions³.

DISCUSSION

The vaginal vaginal microbiota has an important role in the health of the reproductive tract of women; HPV infection is common, rarely recurrent, and occasionally precancerous lesions develop. The greater diversity of vaginal microbiota, combined with reduction of *Lactobacillus* spp., is related to the acquisition and persistence of HPV infection, and the development of precancerous cervical lesions and cervical cancer^{3,9,10,18}. Cervical cancer is common in women from emerging countries and the second most frequent tumor worldwide^{17,19,20}, cervical cancer generally progresses through a series of premalignant lesions¹⁵, where the normal cervical epithelial cell needs

Vaginal Microbiota and its Oncological Risk

around 10-20 years to its malignant transformation and few women who develop CIN evolve to cervical cancer. HPV is the main known risk factor for cervical cancer despite its high prevalence of HPV infection, the incidence and evolution rates of untreated precancerous lesions are low^{13,9,10,18}, 90% HPV-induced infections and lesions are transient or disappear spontaneously,^{3,10} other host and environmental factors are involved during the carcinogenesis process²¹⁻²⁵; as the relationship of vaginal microbiota that plays a role in host susceptibility to persistent HPV infection and the subsequent development of precursor lesions and cervical cancer^{3,9,10,18}, healthy vaginal microbiota is dominated by Lactobacilli that has an immune system local modulates the inflammatory response^{25,26} and controls cell proliferation/apoptosis²⁷⁻²⁹. The protective substances produced by Lactobacilli play an essential role in the balance of vaginal microbiota eubiosis with inhibition of the colonization of other pathogens^{1,2,30} to achieve general health in women.

The importance of chronic inflammation in the development of precancerous lesions and vaginal infections are considered a risk factor for CIN^{1,2,31,32}. Due to the antitumor effect of probiotics and normal maintenance of MV, due to its inhibitory effects on the excessive growth of pathogens in relation to vaginal infections and CIN²⁸. Women with dominant vaginal microbiota CST IV or inert L. are those where injuries persist or progress to cancer; but, it is only an association; They are not the cause. The presence of abnormal MV without Lactobacillus spp. Makes some women susceptible to persistent HPV and the development of CIN and CaCu. Women with BV have higher rates of STIs, including HPV²⁸⁻³¹. HPV infection has an impact on host immune defenses and mucosal metabolism with adverse effects on vaginal microbiota. The infection of the basal membrane of mucosal surfaces by HPV initiates a cascade of mechanisms mediated by inflammation, immune activation of the mucosa with proinflammatory cytokines, interferons, activation of macrophages and NK cells, and integration into viral DNA. All These inflammatory processes and changes of the mucosal immune environment have an impact on vaginal microbiota^{8,15}; This similar increase in diversity and with low lactobacilli is associated with the acquisition or seroconversion of HIV, mainly in the HPV infection that produces changes in vaginal microbiota^{14,28-31}.

It is possible that certain species participate more in the initiation and progression of the disease than others^{8,1,2,30-35}. Metagenomics is a new and interesting

field to identify strains or bacterial genes associated with cervical pathogenesis^{1,2,30}, it is possible to develop rapid tests, microchip for identify patients at higher risk for close monitoring or treatment, the use of probiotics reduce the recurrence of vaginosis bacterial and¹²⁰, elimination of HPV with the anticipation of cervical cancer, will be a great advance in the field of gynecological oncology. Currently, there is a lack of treatment for HPV infection and precursor lesions, the standard reference is surgical, but, it is associated with perinatal morbidity and mortality^{1,2,28-35}.

CONCLUSIONS

There is a relationship between the host and vaginal microbiota, which plays a role in susceptibility to persistent HPV infection and subsequent development of precursor lesions and cervical cancer. It is possible that certain species participate more in the initiation and progression of the disease than others. Early characterization of vaginal microbiota discriminates against women at risk of developing persistent HPV infection for close monitoring or treatment.

REFERENCES

- [1] Vargas-Hernandez VM. Vaginal Microbiota and Bacterial Vaginosis. *Austin J Womens Health*. 2018; 5 (1):1027.
- [2] Vargas-Hernández VM, *Microbiótica Vaginal*. *Rev Trac Gen Inf*. 2016; 9 (1)
- [3] Paweł Łaniewski, Dominique Barnes, Alison Goulder, Haiyan Cui, Denise J. Roe, Dana M. Chase, Melissa M. Herbst-Kralovetz. Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women. *Scientific Reports* 2018;8:7593 | DOI:10.1038/s41598-018-25879-7
- [4] The Cervicovaginal Microbiota and Its Associations with Human Papillomavirus (HPV) Detection in HIV-Infected and HIV-Uninfected Women *J Infec Dis* 2016: 214 (9): jiw374.
- [5] Paweł Łaniewski, Dominique Barnes, Alison Goulder, Haiyan Cui, Denise J. Roe, Dana M. Chase, Melissa M. Herbst-Kralovetz. Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women While high-risk human papillomavirus (HPV) infection is a well-established. *Scientific Reports*. 2018; 8:7593. DOI:10.1038/s41598-018-25879-7

- [6] Mitra A, MacIntyre DA, Lee YS, Smith A, Marchesi JR, Lehne B, Bhatia R, Lyons D, Paraskevaidis E, Li JV, Holmes E, Nicholson JK, Bennett PR, Kyrgiou M. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. *Sci Rep* 2015; 5: 16865. doi: 10.1038/srep16865.
- [7] Audirac-Chalifour A, Torres-Poveda K, Bahena-Román M, Téllez-Sosa J, Martínez-Barnetche J, Cortina-Ceballos B, et al. Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study. *PLoS ONE* 2016; 11 (4): e0153274. <https://doi.org/10.1371/journal.pone.0153274>
- [8] HY Oh, B-S Kim, S-S Seo, J-S Kong, J-K. Lee, S-Y Park, K-M Hong, H-K Kim, M K Kim The association of uterine cervical microbiota with an increased risk for cervical intraepithelial neoplasia in Korea. *Clin Microbiol Infect* 2015; 21: 674 e671-679
- [9] Di Paola M, Sani C, Clemente AM, Iossa A, Perissi E, Castronovo G, Tanturli M, Rivero D, Cozzolino F, Cavalieri D, Carozzi F, De Filippo C, Torcia MG. Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection. *Sci Rep*. 2017 Aug 31; 7 (1): 10200. doi: 10.1038/s41598-017-09842-6.
- [10] Ettore Palma, Nadia Recine, Lavinia Domenici, Margherita Giorgini, Alessandra Pierangeli, Pierluigi Benedetti Panici Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV-infection *BMC Infect Dis*. 2018; 18: 13. doi: 10.1186/s12879-017-2938-z
- [11] B Shannon, TJ Y, S Perusini, P Gajer, B Ma, MS Humphrys, J Thomas-Pavanel, L Chieza, P Janakiram, M Saunders, W Tharao, S Huibner, K Shahabi, J Ravel, A Rebbapragada, R Kaul. Association of HPV infection and clearance with cervicovaginal immunology and the vaginal microbiota. *Mucosal Immunol*. 2017; 10 (5): 1310-1319. doi:10.1038/mi.2016.129.
- [12] Laura L, Reimers Supriya D, Mehta, L. Stewart Massad Robert, D Burk, Xianhong Xie, et al. The Cervicovaginal Microbiota and Its Associations With Human Papillomavirus Detection in HIV-Infected and HIV-Uninfected Women. *J Infect Dis*. 2016; 214 (9): 1361-1369. <https://doi.org/10.1093/infdis/jiw374>
- [13] Vriend HJ, et al. Incidence and persistence of carcinogenic genital human papillomavirus infections in young women with or without Chlamydia trachomatis co-infection. *Cancer medicine*. 2015; 4: 1589-1598.
- [14] Mitra A, David A. MacIntyre, Julian R. Marchesi, Yun S. Lee, Phillip R. Bennett, Maria Kyrgiou. The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next ? *Microbiome* 2016; 4: 58. doi: 10.1186/s40168-016-0203-0
- [15] Amabebe E and Anumba DOC. The Vaginal Microenvironment: The Physiologic Role of Lactobacilli *Front. Med*. 2018; 5: 181. doi: 10.3389/fmed.2018.00181.
- [16] MacIntyre DA, Chandiramani M, Lee YS, Kindinger L, Smith A, Angelopoulos N, Lehne B, Arulkumaran S, Brown R, Teoh TG, Holmes E, Nicholson JK, Marchesi JR, Bennett PR, MacIntyre DA, et al. The vaginal microbiome during pregnancy and the postpartum period in a European population. *Scientific reports*. 2015; 5 doi: 10.1038/srep08988.
- [17] Green KA, Zarek SM, Catherino WH. Gynecologic health and disease in relation to the microbiome of the female reproductive tract. *Fertil Steril*. 2015; 104 (6): 1351-1357. doi: 10.1016/j.fertnstert.2015.10.010.
- [18] Aadra P. Bhatt, Matthew R. Redinbo, Scott J. Bultman. The Role of the Microbiome in Cancer Development and Therapy. *CA Cancer J Clin*. 2017; 8; 67 (4): 326-344. . doi: 10.3322/caac.21398
- [19] Song D, Kong WM, Zhang TQ, Jiao SM, Chen J, Han C, Liu TT. The negative conversion of high-risk human papillomavirus and its performance in surveillance of cervical cancer after treatment: a retrospective study. *Arch Gynecol Obstet*. 2017; 295: 197-203. doi: 10.1007/s00404-016-4197-4
- [20] Vargas-Hernández VM. Screening and Prevention of Cervical Cancer in the World, *World. J Gynecol Res Obstet* 2017; 3 (3): 086-092
- [21] Jespers V, van de Wijgert J, Cools P, Verhelst R, Verstraelen H, Delany-Moretlwe S, Mwaura M, Ndayisaba GF, Mandaliya K, Menten J, Hardy L, Crucitti T; Vaginal Biomarkers Study Group. The significance of Lactobacillus crispatus and

Vaginal Microbiota and its Oncological Risk

- L. vaginalis for vaginal health and the negative effect of recent sex: a cross-sectional descriptive study across groups of African women. *BMC Infect Dis.* 2015 Mar 4; 15: 115. doi: 10.1186/s12879-015-0825-z.
- [22] Gilda Tachedjian, Deirdre E. O'Hanlon, Jacques Ravel. The implausible "in vivo" role of hydrogen peroxide as an antimicrobial factor produced by vaginal microbiota. *Microbiome* 2018; 6: 29 <https://doi.org/10.1186/s40168-018-0418-3>
- [23] Kyrgiou M, Mitra A, Moscicki AB Does the vaginal microbiota play a role in the development of cervical cancer? *Transl Res.* 2017; 179: 168-182
- [24] Wira CR, Rodriguez-Garcia M, Patel MV. The role of sex hormones in immune protection of the female reproductive tract. *Nat Rev Immunol.* 2015; 15 (4): 217-30.
- [25] Pascale Vonaesch, Mark Anderson and Philippe J. Sansonetti. Pathogens, microbiome and the host: emergence of the ecological Koch's postulates *FEMS Microbiology Reviews*, 2018; 42: 273-292. doi: 10.1093/femsre/fuy003
- [26] Charles R. Wira, Marta Rodriguez-Garcia, Mickey V. Patel The role of sex hormones in immune protection of the female reproductive tract *Nature Reviews Immunology* 2015; 15; 217-230. doi:10.1038/nri3819
- [27] Nelson, T.M., Borgogna, J.L., Brotman, R.M. et al. Vaginal biogenic amines: biomarkers of bacterial vaginosis or precursors to vaginal dysbiosis?. *Front Physiol.* 2015; 6: 253
- [28] Recine N, Palma E, Domenici L, et al. Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using *Lactobacillus rhamnosus* BMX 54 as adjuvant treatment against bacterial vaginosis. *Arch Gynecol Obstet.* 2016; 293: 101-107. doi: 10.1007/s00404-015-3810-2.
- [29] Laura L Reimers, Supriya D Mehta, Howard D Srickler. The Cervicovaginal Microbiota and Its Associations with Human Papillomavirus (HPV) Detection in HIV-Infected and HIV-Uninfected Women *J Infec Dis* 2016: 214 (9): jiw374.
- [30] Vargas-Hernández. VM La asociación de la microbiota, virus del papiloma humano y cáncer cervicouterino *Rev Hosp Jua Mex* 2018; 85(1): 6-8
- [31] Thomas RM, Jobin C. The microbiome and cancer: is the 'oncobiome' mirage real?. *Trends Cancer.* 2015; 1: 24-35
- [32] Piyathilake CJ, Ollberding NJ, Kumar R. et al. Cervical microbiota associated with risk of higher grade cervical intraepithelial neoplasia in women infected with high-risk human papillomaviruses. *Cancer Prev Res* 2016; 9: 357-366
- [33] Yarbrough VL, Winkle S, Herbst-Kralovetz MM. Antimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implications. *Hum Reprod Update.* 2015; 21: 353-377
- [34] FH Al-Ghazzewi, RF. Tester Biotherapeutic agents and vaginal health *Journal of Applied Microbiology* 2016; 121 (1): 18-27
- [35] Dona MG, Gheit, T, Latini A. et al. Alpha, beta and gamma human papillomaviruses in the anal canal of HIV-infected and uninfected men who have sex with men. *J Infect.* 2015; 71: 74-84

Citation: Victor Manuel Vargas Hernandez. *Vaginal Microbiota and its Oncological Risk. Archives of Reproductive Medicine and Sexual Health.* 2019; 2 (1): 37-42.

Copyright: © 2019 Victor Manuel Vargas Hernandez. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.